Home > Knowledge > Content
Compound cut diabetes combination therapy will become the mainstream market
Aug 23, 2016

Along with highlights of the clinical effects of combined medication on treatment of diabetes mellitus, large transnational pharmaceutical enterprises ' enthusiasm for the compound preparation of diabetes research and development rising. On January 24, Merck announced in Shanghai, approved by the State food and drug administration, oral tablets to treat type 2 diabetes jienuoda (sitagliptin and metformin tablets) officially launched in China. This is the first in the domestic market of combined oral hypoglycemic drugs.

Chinese medical will diabetes learn branch Deputy, Chairman of the, and second Medic University subsidiary changhai hospital endocrine section Director Zou Dajin pointed out that, jienuoda as compound preparations drop sugar drug, has more strong effect, and more security, and using convenient, and price high, and compliance sex high advantage, and compound preparations by has of these advantage also decided future hypertension, and diabetes, and coronary heart disease, disease management are will is compound preparations of good time.

Subscribe to our email list
Sign up with your name and email to get the latest proway updates, exclusive access to promotions, sales events, pre-order sales & more!
Connect with Sundent Pharm Group
Become our fan, follow us & subscribe for the latest updates and deals
QR Code
  • About Us
  • Products
  • News
  • Knowledge
  • Contact Us
  • Feedback
  • Copyright © Sundent Pharm Group All rights reserved.